Projects per year
Personal profile
Research interests
- Pathogenesis of atherosclerosis
- Treatment of increased cardiovascular risk
specialisation
Collaborations and top research areas from the last five years
Projects
- 2 Active
-
Stroes E.S.G.: Novel anti-atherogenic strategies targeting the vessel wall
Amraoui, F., Bakker, G., van der Bel, R., van den Boogert, M., Bouter, K., Bruikman, C., van Capelleveen, J., Eeftinck Schattenkerk, D., Emans, T., Gilijamse, P., de Groot, P., Hartgers, M., Hartstra, A., Hoogeveen, R., Kootte, R., Lameijer, M., Reeskamp, R., Sabry, A., Sandberg, M., Sjouke, B., Smits, L., Stiekema, L., Surendran, P., Udayappan, S., Verbeek, R., Verweij, S., Zhang, Q., Zheng, K. H., Stroes, E., van den Born, B. H., Dallinga - Thie, G., Hovingh, G., Kastelein, J., Mulder, W., Nederveen, A. & Nieuwdorp, M.
1/06/2008 → …
Project: Research
-
Kastelein J.J.P.: Vascular Medicine
Luirink, I., Roelants, R., Kastelein, J., Dallinga - Thie, G., Defesche, J., Hovingh, G. & Pinto - Sietsma, S.
1/01/2006 → …
Project: Research
-
Correction to: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial (Nature Medicine, (2023), 29, 7, (1782-1792), 10.1038/s41591-023-02427-z)
Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., Hartsfield, C. L., Agollah, G. D., Mansbach, H. & ENTRIGUE Principal Investigators, 2024, (E-pub ahead of print) In: Nature medicine.Research output: Contribution to journal › Comment/Letter to the editor › Academic
Open Access -
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
Cholesterol Treatment Trialists’ (CTT) Collaboration, 2024, (E-pub ahead of print) In: The Lancet Diabetes and Endocrinology.Research output: Contribution to journal › Article › Academic › peer-review
Open Access1 Citation (Scopus) -
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
Raal, F., Durst, R., Bi, R., Talloczy, Z., Maheux, P., Lesogor, A. & on behalf of the ORION-5 Study Investigators, 30 Jan 2024, In: Circulation. 149, 5, p. 354-362 9 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access6 Citations (Scopus) -
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
Santos, R. D., Ruzza, A., Wang, B., Maruff, P., Schembri, A., Bhatia, A. K., Mach, F., Bergeron, J., Gaudet, I., Pierre, J. S., Kastelein, J. J. P., Kees Hovingh, G., Wiegman, A., Gaudet, D. & Raal, F. J., 1 Feb 2024, In: European journal of preventive cardiology. 31, 3, p. 302-310 9 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access2 Citations (Scopus) -
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model
Cupido, A. J., Hof, M. H., de Boer, L. M., Huijgen, R., Stroes, E. S. G., Kastelein, J. J. P., Hovingh, G. K. & Hutten, B. A., 1 Mar 2023, In: Journal of clinical lipidology. 17, 2, p. 236-243 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access2 Citations (Scopus)
Datasets
-
Supplementary Material for: Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia
Kastelein, J. (Contributor), Hallén, J. (Creator), Vige, R. (Creator), Fraser, D. A. (Creator), Zhou, R. (Creator), Hustvedt, S. O. (Creator), Orloff, D. G. (Creator), Bays, H. E. (Creator) & Hallén, J. (Creator), Karger Publishers, 2016
DOI: 10.6084/m9.figshare.5129680, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Icosabutate_a_Structurally_Engineered_Fatty_Acid_Improves_the_Cardiovascular_Risk_Profile_in_Statin-Treated_Patients_with_Residual_Hypertriglyceridemia/5129680
Dataset
-
Supplementary Material for: Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia
Kastelein, J. (Contributor), Hallén, J. (Creator), Vige, R. (Creator), Fraser, D. A. (Creator), Zhou, R. (Creator), Hustvedt, S. O. (Creator), Orloff, D. G. (Creator), Bays, H. E. (Creator) & Hallén, J. (Creator), Karger Publishers, 2016
DOI: 10.6084/m9.figshare.5129680.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Icosabutate_a_Structurally_Engineered_Fatty_Acid_Improves_the_Cardiovascular_Risk_Profile_in_Statin-Treated_Patients_with_Residual_Hypertriglyceridemia/5129680/1
Dataset